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BACKGROUND: To evaluate the impact of change in the hormone receptor (HR) status (HR status conversion) on the long-term
outcomes of breast cancer patients treated with neoadjuvant chemotherapy (NAC).
METHODS: We investigated 368 patients for the HR status of their lesions before and after NAC. On the basis of the HR status and the
use/non-use of endocrine therapy (ET), the patients were categorised into four groups: Group A, 184 ET-administered patients with
HR-positive both before and after NAC; Group B, 47 ET-administered patients with HR status conversion; Group C, 12 ET-naive
patients with HR status conversion; Group D, 125 patients with HR-negative both before and after NAC.
RESULTS: Disease-free survival in Group B was similar to that in Group A (hazard ratio, 1.16; P¼0.652), but that in Group C was
significantly lesser than that in Group A (hazard ratio, 6.88; Po0.001). A similar pattern of results was obtained for overall survival.
CONCLUSION: Our results indicate that the HR status of tumours is a predictive factor for disease-free and overall survival and that ET
appears to be suitable for patients with HR status conversion. Therefore, both the CNB and surgical specimens should be monitored
for HR status.
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Neoadjuvant chemotherapy (NAC) was introduced in the early
1980s for patients with locally advanced breast cancer, initially to
improve the operability of tumours (Kaufmann et al, 2003).
Recently, the application of this therapy has been extended to cases
of operable disease. The previously reported results of a meta-
analysis indicated that neoadjuvant and adjuvant chemotherapy
are equivalent in terms of overall survival (OS) and disease-free
survival (DFS) (Mauri et al, 2005). As the pertinent published
reports present conflicting views, the actual indications for NAC
remain controversial.
Before the initiation of NAC, core-needle biopsy (CNB) is often
performed to establish the histological diagnosis and to assess
certain factors considered predictive of treatment outcomes. The
hormone receptor (HR) status is one such factor. Although this
status is known to change after NAC (Bottini et al, 1996; Lee et al,
2003; Taucher et al, 2003; Colleoni et al, 2004; Burcombe et al,
2005; Shet et al, 2007; Tacca et al, 2007; Kasami et al, 2008;
Neubauer et al, 2008), its impact on long-term outcomes has not
been assessed. The objective of this retrospective study was to
evaluate the frequency and impact of change in the HR status
(HR status conversion) on the long-term outcomes in the
NAC-administered breast cancer patients.
MATERIALS AND METHODS
Patients
We selected 459 primary breast cancer patients treated at the
National Cancer Center Hospital between May 1995 and July 2007.
All the patients had received anthracycline- and taxane-based
NAC. The clinical stages of the patients ranged from cT2N0M0 to
cT4dN3M0, which includes inflammatory (T4d) carcinoma. Data
were collected on the pre- and post-NAC statuses of oestrogen
receptor (ER), progesterone receptor (PgR), and human epidermal
receptor (HER) 2 expressions in the lesions. Patients in whom
pathologic complete response (pCR) was obtained (91 patients)
after surgery, including those with only residual ductal carcinoma
in situ (DCIS), were excluded from this analysis because the HR
status of the lesions of these patients could not be accurately
evaluated. The remaining 368 patients were classified into four
groups on the basis of the HR status of their lesions before and
after NAC and the use/non-use of endocrine therapy (ET): Group
A, 184 ET-administered patients with lesions that were HR-positive
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sboth before and after NAC; Group B, 47 ET-administered patients
with lesions showing HR status conversion; Group C, 12 ET-naive
patients with lesions showing HR status conversion; Group D, 125
patients with lesions that were HR-negative both before and after
NAC. The mean age at the time of diagnosis of breast cancer was
almost the same in the four groups.
Hormone status and HER2 status determination
All the patients underwent CNB performed using an 18G needle.
The ER, PgR, and HER2 statuses of all the CNB and surgical
specimens were determined by immunohistochemistry (IHC).
Details regarding the antibodies used, the clones used, and the
time periods for which they were used, as well as the antigen
retrieval and the source of antibodies for IHC studies, are listed in
Table 1. Positive staining for ER/PgR was defined as nuclear
staining in X10% of the tumour cells. HER2 protein over-
expression was defined as with 3þ complete membrane staining.
If HER2 staining on IHC was determined to be 2þ, fluorescent
in situ hybridisation (FISH) was used to confirm the results. FISH
was performed using the PathVysion kit (Abott-Vysis Lab, Abott
Park, IL, USA). HER2 gene amplification was defined as a
HER2:chromosome 17 ratio of X2.1. HR positivity was defined
as positivity for ER and/or PgR. The Allred scoring system was
used to assess the degree of staining (Allred et al, 1998). Standard
controls were prepared on a daily basis for each tumour to ensure
the results of IHC.
Tumour size determination and evaluation of neoadjuvant
chemotherapy response
Before each chemotherapy treatment and before surgery, the two
greatest perpendicular diameters of the tumours in the breast and
axillary nodes were measured, and the products of these diameters
were added as a measure of total tumour size. No clinical response
of palpable tumour in the breast and axillary lymph nodes was
defined as a complete response (CR). Reduction in total tumour
size of 50% or greater was graded as a partial response (PR). An
increase in total tumour size of more than 50% or the appearance
of new suspicious ipsilateral axillary adenopathy was considered as
a progressive disease (PD). Tumours that did not meet the criteria
for objective response or progression were considered as a stable
disease (SD).
Chemotherapy
Patients receiving NAC were administered an anthracycline and a
taxane, either concurrently or sequentially. Those receiving
concurrent therapy were administered four cycles (doxorubicin
at 50mgm
 2 plus docetaxel at 60mgm
 2) every 21 days. Patients
showing clinical CR or PR to the above treatment were
administered two additional cycles of the same regimen after
the surgery. However, patients who did not achieve objective
clinical response to NAC were administered with four cycles of
5-fluorouracil (600mgm
 2), methotrexate (40mgm
 2), and
cyclophosphamide (600mgm
 2) after the surgery. For patients
receiving the sequential regimen, four cycles of 5-fluorouracil
(500mgm
 2), epirubicin (100mgm
 2), cyclophosphamide
(500mgm
 2) or doxorubicin (60mgm
 2), and cyclophosphamide
(600mgm
 2) were administered every 21 days, followed by a
taxane. As a taxane, paclitaxel was administered weekly at a dose of
80mgm
 2 per week for 12 weeks or at a dose of 175mgm
 2 every
3 weeks for four cycles, or docetaxel was administered every 3
weeks at a dose of 75mgm
 2 for four cycles.
Adjuvant endocrine therapy (ET) and irradiation
Adjuvant radiotherapy was administered to patients who under-
went breast-conserving surgery. Adjuvant radiotherapy was
recommended to those who underwent modified radical
mastectomy for the disease ranging from cT3N1M0 to cT4dN3M0.
The decision to administer ET was taken on the basis of the
treating physician’s and/or the patient’s preferences. Most patients
with HR-positive lesions were administered 20mg of tamoxifen
daily for 5 years. From 2005 onwards, postmenopausal women
taking tamoxifen were (1) allowed to switch to an aromatase
inhibitor before completing 5 years of tamoxifen, (2) allowed to
begin taking an aromatase inhibitor after a 5-year course of
tamoxifen or (3) recommended an aromatase inhibitor for the first
5 years.
Statistical analysis
The frequencies and descriptive statistics of the demographic and
clinical variables from the four groups—A, B, C, and D—were
obtained. The ER and PgR statuses of the lesions before and after
NAC were compared using the consistency test. DFS was defined as
the time from surgery to the detection of relapse, death from any
cause, or the date of the last visit for patients without events. OS
was defined as the time from surgery to death from any cause or
the date of the last visit for patients without events. DFS and OS
were estimated using the Kaplan–Meier method, and the survival
curves were compared using the log-rank test. Multivariate
Cox regression analysis with stepwise selection (a¼0.05) was
used to estimate the hazard ratio, 95% confidence interval
(CI), and the effects of the clinical and pathological variables. A
two-sided Po0.05 was considered to be statistically significant. All
the analyses were performed using the SAS (version 9.1; SAS
Institute Inc., Cary, NC, USA).
Table 1 Panel of antibodies
Antigen Period used for Clone Type Antigen retrieval Source
ER Until Oct 2002 1D5 Mouse monoclonal A/C citrate buffer Dako
From Nov 2002 to Feb 2005 ER88 Mouse monoclonal As above Bio Genex
From Mar 2005 1D5 Mouse monoclonal As above Dako
PgR Until Oct 2002 1A6 Mouse monoclonal As above Novocastra
From Nov 2002 to Feb 2005 PR88 Mouse monoclonal As above Bio Genex
From Mar 2005 PgR636 Mouse monoclonal As above Dako
HER2 Until Oct 2002 c-erbB-2 Rabbit polyclonal As above Dako
From Nov 2002 to Feb 2005 CB11 Mouse monoclonal As above Bio Genex
From Mar 2005 c-erbB-2 Rabbit polyclonal As above Dako
Abbreviations: A/C: autoclave for 10min at 1211C; ER: estrogen receptor; HER2: human epidermal receptor 2; PgR: progesterone receptor; citrate buffer: 10mM citrate buffer,
pH 6.0.
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Characteristics Group A (N¼184) Group B (N¼47) Group C (N¼12) Group D (N¼125)
Mean±StdDev age, years 48.7±9.9 49.0±9.5 49.5±8.1 49.7±8.8
Tumour stage
T1 1 (0.5) 0 (0.0) 1 (8.3) 1 (0.8)
T2 99 (53.8) 20 (42.6) 4 (33.3) 52 (41.6)
T3 46 (25.0) 19 (40.4) 5 (41.7) 50 (40.0)
T4a–c 36 (19.6) 6 (12.8) 2 (16.7) 20 (16.0)
T4d 2 (1.1) 2 (4.3) 0 (0.0) 2 (1.6)
N stage
N0 95 (51.6) 22 (46.8) 5 (41.7) 55 (44.0)
N1 67 (36.4) 21 (44.7) 6 (50.0) 51 (40.8)
N2 16 (8.7) 4 (8.5) 1 (8.3) 15 (12.0)
N3 6 (3.3) 0 (0.0) 0 (0.0) 4 (3.2)
Clinical stage
IIA 59 (32.1) 12 (25.5) 2 (16.7) 26 (20.8)
IIB 49 (26.6) 15 (31.9) 5 (41.7) 39 (31.2)
IIIA 35 (19.0) 12 (25.5) 3 (25.0) 34 (27.2)
IIIB 36 (19.6) 8 (17.0) 2 (16.7) 22 (17.6)
IIIC 5 (2.7) 0 (0.0) 0 (0.0) 4 (3.2)
Histological grade
G1 14 (7.61) 3 (6.4) 1 (8.3) 2 (1.6)
G2 111 (60.3) 26 (55.3) 4 (33.3) 40 (32.0)
G3 57 (31.0) 16 (34.0) 7 (58.3) 78 (62.4)
Unknown 2 (1.1) 2 (4.3) 0 (0.0) 5 (4.0)
HR status before NAC
Positive 184 (100.0) 29 (61.7) 1 (8.3) 0 (0.0)
Negative 0 (0.0) 18 (38.3) 11 (91.7) 125 (100.0)
HER2 status before NAC
Positive 34 (18.5) 17 (36.2) 4 (33.3) 57 (45.6)
Negative 150 (81.5) 30 (63.8) 8 (66.7) 68 (54.4)
HR status after NAC
Positive 184 (100.0) 18 (38.3) 11 (91.7) 0 (0.0)
Negative 0 (0.0) 29 (61.7) 1 (8.3) 125 (100.0)
HER2 status after NAC
Positive 26 (14.1) 18 (38.3) 4 (33.3) 55 (44.0)
Negative 158 (85.9) 29 (61.7) 8 (66.7) 70 (56.0)
NAC regimen
AT 69 (37.5) 22 (46.8) 10 (83.3) 62 (49.6)
AC followed by T 56 (30.4) 9 (19.2) 2 (16.7) 24 (19.2)
CEF followed by T 59 (32.1) 16 (34.0) 0 (0.0) 39 (31.2)
Clinical response
CR/PR 157 (85.3) 40 (85.1) 12 (100.0) 103 (82.4)
SD/PD 27 (14.7) 7 (14.9) 0 (0.0) 22 (17.6)
Operation
Lumpectomy 65 (35.3) 18 (38.3) 3 (25.0) 40 (32.0)
Mastectomy 119 (64.7) 29 (61.7) 9 (75.0) 85 (68.0)
Radiotherapy
Yes 127 (69.0) 30 (63.8) 9 (75.0) 82 (65.6)
No 57 (31.0) 17 (36.2) 3 (25.0) 43 (34.4)
Number of lymph node metastases
0 65 (35.3) 22 (46.8) 3 (25.0) 58 (46.4)
1–3 59 (32.1) 13 (27.7) 5 (41.7) 42 (33.6)
44 60 (32.6) 12 (25.5) 4 (33.3) 25 (20.0)
Endocrine therapy
TAM, 5 years 112 (60.9) 30 (63.8) 0 (0.0) 0 (0.0)
TAM followed by AI 44 (23.9) 11 (23.4) 0 (0.0) 0 (0.0)
AI, 5 years 28 (15.2) 6 (12.8) 0 (0.0) 0 (0.0)
None 0 (0.0) 0 (0.0) 12 (100.0) 125 (100.0)
Abbreviations: AC¼doxorubicin and cyclophosphamide; AI¼aromatase inhibitor; AT¼doxorubicin and docetaxel; CEF¼cyclophosphamide, epirubicin and 5-fluorouracil;
ER¼estrogen receptor; HER2¼human epidermal receptor; N¼number of patients; PgR¼progesterone receptor; T¼taxane (weekly or triweekly paclitaxel, or triweekly
docetaxel); TAM¼tamoxifen; Figures in parentheses are percentage of patients except for age.
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Patient characteristics
Among the 459 NAC-administered patients, pCR after surgery
was achieved in 91 patients. Pathological assessment of the CNB
specimens of patients with pCR revealed that 26 (28.6%) and 19
(20.9%) patients, respectively, were ER-positive and PgR-positive
and that 63 (69.2%) were negative for both ER and PgR.
Examination of the surgical specimens revealed residual
invasive disease in 368 patients. The distribution of these patients
in the four groups was as follows: Group A, 184 (50.0%) patients;
Group B, 47 (12.8%) patients; Group C, 12 (3.3%) patients; Group
D, 125 (34.0%) patients.
The patient and tumour characteristics of the four groups are
listed in Table 2. The postoperative performance status (PS 0 or 1)
of all the patients was good. HR status conversion after NAC was
observed in 59 (16.0%) patients. None of the HER2-positive
patients were administered trastuzumab during neoadjuvant or
adjuvant chemotherapy. Twelve (3.3%) did not receive adjuvant
ET, although it was not contraindicated, but all of their lesions
showed HR status conversion after NAC. All patients whose lesions
showed ER status from positive to negative after chemotherapy
had been administered ET.
Change in the HR status and HER2 status
The typical staining patterns of the CNB and surgical specimens
are shown in Figure 1. The pre- and post-NAC ER and PgR statuses
are shown in Table 3. Lesions of 23 (6.3%) patients showed a
change in both the ER and PgR statuses after NAC. The HR and
HER2 statuses changed from positive to negative in 30 (8.2%) and
22 (6.0%) patients, and changed from negative to positive in 29
(7.9%) and 13 (3.5%) patients, respectively.
Figures 2 and 3 show the pre- and post-NAC proportion,
intensity, and total scores of ER and PgR staining, determined on
the basis of the Allred scoring system, for patients who underwent
a change in the HR status. As shown in Figures 2 and 3, the
changes in the ER and PgR statuses were observed not only in
cases with borderline positive (total score 3–5) staining but also in
those with strongly positive (total score 7–8) staining. The change
in the HR status was not caused by a change in only the proportion
or intensity scores of ER and PgR. In addition, Figure 4 shows the
results of HER2 testing in the 59 patients who showed HR status
conversion.
Long-term outcomes
The median duration of follow-up was 47 months. Figure 5 shows
the Kaplan–Meier curves for DFS in the four groups. The
differences among the four curves were statistically significant,
Figure 1 Immunostaining for oestrogen receptor in core needle biopsy and surgery specimens after neoadjuvant chemotherapy. (A) Staining of tumour
cells in core-needle biopsy sample (CNB) staining positively for oestrogen receptor (ER). (B) Staining of tumour cells in surgical samples with ER-negative
status after neoadjuvant chemotherapy (NAC). (C) Staining of tumour cells in CNB specimens with ER-negative status. (D) Staining of tumour cells in
surgical samples with ER-positive status after NAC.
Table 3 Number of patients classified by estrogen receptor and
progesterone receptor statuses before and after neoadjuvant chemotherapy
(ER, PgR) after NAC
(ER, PgR) before NAC (+, +) (+, –) (–, +) (–, –)
(+, +) 69 (18.8) 41 (11.1) 3 (0.8) 10 (2.7)
(+,  ) 18 (4.9) 27 (7.3) 1 (0.3) 7 (1.9)
( , +) 11 (3.0) 6 (1.6) 8 (2.2) 13 (3.5)
( ,  ) 6 (1.6) 11 (3.0) 12 (3.3) 125 (34.0)
Abbreviations: ER¼estrogen receptor; HER2¼human epidermal receptor 2;
PgR¼progesterone receptor. Figures in parentheses are percentage of patients.
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rates in Groups A, B, C, and D were 80.3, 78.4, 36.4, and 72.2%,
respectively.
Table 4 shows the results of the multivariate Cox regression
analysis of DFS with stepwise selection. The following six variables
were chosen as prognostic factors for inclusion in the Cox
proportional hazard model: age (o35 vs X35 years), clinical stage
at diagnosis (IIA and IIB, or IIIA vs IIIB or IIIC), histological grade
(1 vs 2 and 3), HER2 status (positive vs negative), clinical response
(CR, PR vs SD, PD), and the number of lymph node metastases
(0 vs 1–3vs X4). Three of these variables—the HER2 status, clinical
response to NAC, and the number of lymph node metastases—were
identified by the stepwise selection method in the multivariate Cox
regression model as the variables affecting the DFS.
The DFS of Groups B and A was similar (hazard ratio, 1.16; 95%
CI, 0.61–2.19), whereas that of Group C was significantly shorter
than that of Group A (hazard ratio, 6.88; 95% CI, 3.00–15.80).
Table 5 summarises the results of the analysis of the efficacy of ET
in the 59 patients who showed HR status conversion by using the
multivariate Cox regression model. The DFS of the ET-adminis-
tered patients was significantly longer than that of ET-naive
patients (hazard ratio, 0.19; 95% CI, 0.06–0.60; Po0.004).
Figure 6 shows the Kaplan–Meier curves for OS in the four
groups. The differences among the four curves were statistically
significant, as determined by the log-rank test (P¼0.035). The
5-year survival rates of Groups A, B, C, and D were 90.3, 86.3, 58.9,
and 78.2%, respectively. The pattern of results of the analyses for
OS in the four groups was similar to that for DFS.
DISCUSSION
This is the first report on the long-term outcomes and impact of
adjuvant ET in patients with HR status conversion after NAC.
In this study, the DFS and the OS of ET-administered patients
with HR status-converted lesions were similar to those of
ET-administered patients with lesions that were HR-positive both
before and after NAC, whereas the DFS of ET-naive patients whose
lesions show HR status conversion was significantly shorter than
that of ET-administered patients whose lesions were HR-positive
both before and after NAC. Analysis of OS yielded results similar
to that pertaining to DFS. These findings indicate that the change
in the status alone did not seem to influence the long-term
outcome; rather, the non-administration of adjuvant ET seemed to
be associated with a worse prognosis.
ER, PgR, and HER2 status changes were observed in 14.9, 29.1,
and 9.5% of the patients included in our study. The overall
frequency of patients with HR status conversion was 16.0%. This
incidence of HR status conversion was similar to previous reports
on post-NAC change in the ER, PgR, and HER2 statuses, which
reported incidences of 8–28%, 6–59% (Bottini et al, 1996; Lee
et al, 2003; Taucher et al, 2003; Colleoni et al, 2004; Burcombe
et al, 2005; Shet et al, 2007; Kasami et al, 2008; Neubauer et al,
2008), and 0–21% (Bottini et al, 1996; Colleoni et al, 2004; Arens
et al, 2005; Burcombe et al, 2005; Quddus et al, 2005; Adams et al,
2008; Kasami et al, 2008; Neubauer et al, 2008), respectively.
Although the rate of cases with no change in the HR status after
NAC was high, the incidence of change in the HR status is
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sclinically not negligible. The poor prognosis of patients with HR
status conversion not administered adjuvant ET indicates the
necessity to determine the HR status of the lesions both before and
after NAC and to administer ET to patients with HR status
conversion.
Despite yielding these clinically relevant findings, our study is
limited in some aspects: (1) The patient groups studied were
heterogeneous in terms of sample size and characteristics. (2) This
study was retrospective and the results of the statistical tests were
not based on randomisation, but were exploratory, although the
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fluorescent in situ hybridisation (FISH).
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Figure 5 Kaplan–Meier curves of disease-free survival in four groups.
Short vertical lines indicate censored data points. Log-rank test was
significant for disease-free survival (DFS) (P¼0.008).
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analysis. Therefore, the impact of the change in the pre- and post-
NAC HR statuses on the long-term outcomes and the efficacy of ET
for patients with HR status conversion should be evaluated using a
prospective study design. (3) The methods for measuring the ER
and PgR status varied with the age of the patients, as shown in
Table 1. Although the methods used for the determination of
the HR statuses of the tumours of 36 patients among 368 patients
were measured using different methods for the CNB and
surgical specimens, only three of these tumours showed HR status
conversion. A previous report showed that the HR status
conversion occurred in 23% of the population in a study in which
the same methods were used for the analysis of CNB and surgical
specimens (Tacca et al, 2007), whereas HR status conversion was
observed in 16.0% (59 patients) of the patients in this study.
Therefore, the difference in the methods for measuring the ER and
PgR statuses of the CNB and surgical specimens seems not to be
the only reason for HR-status conversion.
In conclusion, our study showed that the prognosis of patients
with change in HR status after NAC but who did not receive ET
was worse than that of the other groups. The hormone receptor
status should be evaluated not only in the biopsy specimens
obtained before the initiation of NAC but also in specimens
obtained during post-NAC surgery; the pre- and post-NAC HR
statuses will help determine the indication for adjuvant ET in
patients. ET appears to be suitable for patients with tumours
positive for HR status at least once, that is, either before or
after NAC.
ACKNOWLEDGEMENTS
We thank Dr Yuko Sasajima and Dr Hitoshi Tsuda of the
Department of Pathology, National Cancer Center Hospital, for
help with the pathological review. This study was supported by a
grant from the Ministry of Health, Labour and Welfare (H21-4-4).
Conflict of interest
The authors declare that there are no competing financial interests.
REFERENCES
Adams AL, Eltoum I, Krontiras H, Wang W, Chhieng DC (2008) The effect
of neoadjuvant chemotherapy on histologic grade, hormone receptor
status, and Her2/neu status in breast carcinoma. Breast J 14: 141–146
Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and
predictive factors in breast cancer by immunohistochemical analysis.
Mod Pathol 11: 155–168
Table 4 Results of multivariate Cox regression analysis of disease-free
survival with stepwise selection
Variables Hazard ratio (95% CI) P-value
Group
A1
B 1.16 (0.61, 2.19) 0.652
C 6.88 (3.00, 15.80) o0.001
D 1.63 (1.01, 2.63) 0.045
Clinical stage
IIA/IIB/IIIA 1
IIIB/IIIC 1.56 (1.00, 2.42) 0.049
HER2
Negative 1
Positive 2.00 (1.30, 3.09) 0.002
Clinical response
SD/PD 1
PR/CR 0.56 (0.34, 0.92) 0.021
Number of lymph node metastases
01
1–3 2.09 (1.14, 3.83) 0.017
44 6.49 (3.71, 11.37) o0.001
Abbreviations: CI¼confidence interval; CR¼complete response; PR¼partial
response; SD¼stable disease; PD¼progression disease.
Table 5 Efficacy of endocrine therapy in patients with lesions showing
hormone receptor status conversion after neoadjuvant chemotherapy in
terms of disease-free survival
Variables Hazard ratio (95% CI) P-value
ET
No 1
Yes 0.19 (0.06, 0.60) 0.004
HER2
Negative 1
Positive 1.58 (0.46, 5.42) 0.467
Clinical response
SD/PD 1
PR/CR 0.75 (0.15, 3.93) 0.738
Clinical stage
IIA/IIB/IIIA 1
IIIB/IIIC 1.03 (0.26, 4.16) 0.968
Number of lymph node metastases
01
1–3 2.74 (0.63, 11.98) 0.181
44 14.66 (3.24, 66.43) 0.001
Abbreviations: CI¼confidence interval; CR¼complete response; PR¼partial
response; SD¼stable disease; PD¼progression disease.
Group A
P
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
0.0
0.2
0.4
0.6
0.8
1.0
Time after surgery (year)
Group D Group C Group B
01 0 9 8 7 6 5 4 3 2 1
Figure 6 Kaplan–Meier curves of OS in four groups. Short vertical lines
indicate censored data points. Log-rank test was significant for overall
survival (OS) (P¼0.035).
Change in hormone receptor after NAC
T Hirata et al
1535
British Journal of Cancer (2009) 101(9), 1529–1536 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sArens N, Bleyl U, Hildenbrand R (2005) HER2/neu, p53, Ki67, and
hormone receptors do not change during neoadjuvant chemotherapy in
breast cancer. Virchows Arch 446: 489–496
Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, Cirillo F,
Bolsi G, Bertoli G, Alquati P, Dogliotti L (1996) Effect of neoadjuvant
chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid
hormone receptor status in human breast tumours. Anticancer Res 16:
3105–3110
Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright
D, Allen SA, Dove J, Wilson GD (2005) Evaluation of ER, PgR, HER-2
and Ki-67 as predictors of response to neoadjuvant anthracycline
chemotherapy for operable breast cancer. Br J Cancer 92: 147–155
Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD,
Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nole ` F,
Peruzzotti G, Goldhirsch A (2004) Chemotherapy is more effective in
patients with breast cancer not expressing steroid hormone receptors: a
study of preoperative treatment. Clin Cancer Res 10: 6622–6628
Kasami M, Uematsu T, Honda M, Yabuzaki T, Sanuki J, Uchida Y,
Sugimura H (2008) Comparison of estrogen receptor, progesterone
receptor and Her-2 status in breast cancer pre- and post-neoadjuvant
chemotherapy. Breast 17: 523–527
Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W,
Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek
R, Souchon R, Tulusan AH, Volm T, Senn HJ (2003) International expert
panel on the use of primary (preoperative) systemic treatment of
operable breast cancer: review and recommendations. J Clin Oncol 21:
2600–2608
Lee SH, Chung MA, Quddus MR, Steinhoff MM, Cady B (2003) The effect of
neoadjuvant chemotherapy on estrogen and progesterone receptor
expression and hormone receptor status in breast cancer. Am J Surg
186: 348–350
Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant
systemic treatment in breast cancer: meta-analysis. J Natl Cancer Inst 97:
188–194
Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E,
Fehm T (2008) Changes in tumour biological markers during primary
systemic chemotherapy (PST). Anticancer Res 28: 1797–1804
Quddus RM, Sung JC, Zhang C, Pasqueriello T, Eklund M, Steinhoff MM
(2005) HER-2/neu expression in locally advanced breast carcinomas:
Pre-and post-neoadjuvant chemotherapy. Breast Cancer 12: 294–298
Shet T, Agrawal A, Chinoy R, Havaldar R, Parmar V, Badwe R (2007)
Changes in the tumor grade and biological markers in locally advanced
breast cancer after chemotherapy-implications for a pathologist. Breast J
13: 457–464
Tacca O, Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I,
Durando X, Achard JL, Gimbergues P, Cure ´ H, Chollet P (2007) Changes
in and prognostic value of hormone receptor status in a series of
operable breast cancer patients treated with neoadjuvant chemotherapy.
Oncologist 12: 636–643
Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, Bachleitner
T, Kandioler D, Wenzel C, Steger G, Mittlbo ¨ck M, Jakesz R (2003)
Sequential steroid hormone receptor measurements in primary breast
cancer with and without intervening primary chemotherapy. Endocr
Relat Cancer 10: 91–98
Change in hormone receptor after NAC
T Hirata et al
1536
British Journal of Cancer (2009) 101(9), 1529–1536 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s